In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Gram-negative foot infection
Not to be taken lightly
- Severe asthma
Anti-IL-5/-5Rα biologics impress in the real world
- Significance, diagnostics and treatment options for cardiology practice
Coronary artery spasm and atherosclerosis
- Smoldering multiple myeloma
Daratumumab delays progression in smoldering multiple myeloma
- Invitation to the 12th IBD Roadshow | June 23-25, 2025 | with Professor Bruce Sands
Acceleration in IBD Treatment: How early and holistic care leads to better outcomes
- Chronic hand eczema
Changing therapy landscape – a lot is happening
- Chronic obstructive pulmonary disease
Polygenic risk score can help identify COPD
- Bronchiectasis and Pseudomonas aeruginosa infection